Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Burning Rock Biotech (BNR) EBIT (2020 - 2025)

Historic EBIT for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to -$2.3 million.

  • Burning Rock Biotech's EBIT rose 5878.18% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.2 million, marking a year-over-year increase of 7212.2%. This contributed to the annual value of -$49.0 million for FY2024, which is 4803.6% up from last year.
  • As of Q3 2025, Burning Rock Biotech's EBIT stood at -$2.3 million, which was up 5878.18% from -$1.6 million recorded in Q2 2025.
  • Over the past 5 years, Burning Rock Biotech's EBIT peaked at -$1.6 million during Q2 2025, and registered a low of -$41.5 million during Q1 2022.
  • Moreover, its 5-year median value for EBIT was -$24.5 million (2023), whereas its average is -$22.0 million.
  • Per our database at Business Quant, Burning Rock Biotech's EBIT plummeted by 20269.9% in 2021 and then skyrocketed by 8951.25% in 2025.
  • Over the past 5 years, Burning Rock Biotech's EBIT (Quarter) stood at -$39.6 million in 2021, then increased by 20.32% to -$31.5 million in 2022, then rose by 25.69% to -$23.4 million in 2023, then skyrocketed by 52.09% to -$11.2 million in 2024, then soared by 79.8% to -$2.3 million in 2025.
  • Its EBIT stands at -$2.3 million for Q3 2025, versus -$1.6 million for Q2 2025 and -$2.1 million for Q1 2025.